he AstraZeneca vaccine has been renamed Vaxzevria following a situation in Europe where many countries have suspended supplies, Sweden's Medical Products Agency noted.

According to the regulator, the name change does not bring about changes in other drug parameters. However, the labeling and packaging of the new product may differ.

A number of European countries have suspended or banned the vaccination of AstraZeneca after the detection of thrombosis in vaccinated patients.

The creators of the drug insist on its safety. The company noted that a study of the health of more than 17 million people after vaccination showed no increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia.